Tomas Ahlgren

A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony‐stimulating factor: significant effects on quality of life

Eva Hellström‐Lindberg, Nina Gulbrandsen, Greger Lindberg et al. · British Journal of Haematology · 2003 · 454 citations · Full text

Medicine, Hematology, Pharmacotherapy +16

Treatment of Anemia in Myelodysplastic Syndromes With Granulocyte Colony-Stimulating Factor Plus Erythropoietin: Results From a Randomized Phase II Study and Long-Term Follow-Up of 71 Patients

Eva Hellström-Lindberg, Tomas Ahlgren, Yves Béguin et al. · Blood · 1998 · 306 citations · Full text

Medicine, Hematology, Pharmacotherapy +14

Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976–1993 and on 5098 unselected cases reported in the literature 1974–2001

Nils Mauritzson, María Albin, Lars Rylander et al. · Leukemia · 2002 · 265 citations

Medicine, Hematology, Oncology +17

In vitro biosynthesis of cold insoluble globulin (fibronectin) by mouse peritoneal macrophages

Staffan Johansson, Kristofer Rubin, Magnus Höök et al. · FEBS Letters · 1979 · 82 citations · Full text

Life Sciences, Biochemistry, Immunology +6

A single‐center population‐based consecutive series of 1500 cytogenetically investigated adult hematological malignancies: karyotypic features in relation to morphology, age and gender

Nils Mauritzson, Bertil Johansson, María Albin et al. · European Journal Of Haematology · 1999 · 65 citations

Medicine, Hematology, Oncology +17